ZV
Zevra Therapeutics, Inc.
ZVRA · NASDAQ
$11.04 -2.21% (-$0.25)
1M -4.58%
Market Cap $665.6M
P/E Ratio 11.42x
Div. Yield -
ROE 32.77%
Bulios Fair Price
$11.94
8.2% upside
Current Price
$11.04
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ZVRA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
80 /100
Cheap P/E 11.42x
EV/EBITDA 7.15x
P/FCF 20.40x
Growth
100 /100
Growing Rev. growth 118.82%
Book val. growth 27.21%
EPS growth N/A
Profitability
100 /100
Strong Gross margin 94.96%
Net margin 42.82%
FCF margin 23.98%
Quality
78 /100
Excellent ROIC 12.90%
ROE 32.77%
Asset turnover 0.45x
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 5.17x
Net debt/EBITDA -1.97x
Stability
27 /100
Unstable Beta 0.95x
Rev. volatility 182.47%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ZVRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Neil F. McFarlane
Employees
61
Headquarters
Boston
Upcoming events
04 NOV
Earnings
Upcoming earnings report